New York, NY - Altaris, LLC (collectively with its managed funds, “Altaris”), today announced that it has entered into a definitive agreement to acquire the Life Sciences & Healthcare business (“LS&H”) from Clarivate plc (NYSE: CLVT). LS&H is comprised of the Cortellis and Decision Resources Group (DRG) portfolios and will operate as an independent company under Altaris’ ownership following the closing of the transaction. The transaction is expected to close in the second half of 2026, subject to the satisfaction of customary closing conditions and receipt of required regulatory approvals.
LS&H is an AI-enabled data intelligence products and services business supporting R&D and commercialization decisions for pharmaceutical, biotechnology, and medical technology companies. The Cortellis platform delivers R&D intelligence across drug development, regulatory, and safety use cases; the DRG platform supports commercialization and market access decisions through epidemiology, forecasting, and payer insights. The business serves approximately 2,500 customers globally, including the top 20 pharmaceutical companies.
The transaction will establish LS&H as a scaled, independent life sciences intelligence platform with the focus and resources to accelerate product innovation, strengthen go-to-market execution, and support customers across the full R&D and commercialization lifecycle.
Advisors
J.P. Morgan Securities LLC is acting as exclusive financial advisor, and Kirkland & Ellis LLP is acting as legal counsel to Altaris.
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $9+ billion of equity capital. For more information, please visit www.altariscap.com.